Cargando…

Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study

OBJECTIVES: The COVID-19 pandemic and the consequent lockdown came as a storm disrupting people’s everyday life. This study aimed at observing whether the COVID-19 related lockdown influenced migraine frequency and disability in migraine patients on therapy with monoclonal antibodies inhibiting the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Altamura, Claudia, Cevoli, Sabina, Aurilia, Cinzia, Egeo, Gabriella, Fofi, Luisa, Torelli, Paola, Brunelli, Nicoletta, Pierangeli, Giulia, Favoni, Valentina, Fallacara, Adriana, Pensato, Umberto, Barbanti, Piero, Vernieri, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Covid-19
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527669/ https://www.ncbi.nlm.nih.gov/pubmed/33001407 http://dx.doi.org/10.1007/s10072-020-04767-x

Ejemplares similares

Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
por: Vernieri, Fabrizio, et al.
Publicado: (2021)

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
por: Vernieri, Fabrizio, et al.
Publicado: (2021)

Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache
por: Pensato, Umberto, et al.
Publicado: (2022)

A proposal for a national registry on chronic migraines
por: Vanacore, Nicola, et al.
Publicado: (2015)

Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
por: Barbanti, Piero, et al.
Publicado: (2022)

Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT study
por: Vernieri, Fabrizio, et al.
Publicado: (2022)

Chronic migraine: treatability, refractoriness, pseudo-refractoriness
por: Barbanti, Piero, et al.
Publicado: (2015)

Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment
por: Fofi, Luisa, et al.
Publicado: (2022)

Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience
por: Altamura, Claudia, et al.
Publicado: (2022)

Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial
por: Barbanti, Piero, et al.
Publicado: (2012)

Gepants — a long way to cure: a narrative review
por: Altamura, Claudia, et al.
Publicado: (2022)

Botulinum Neurotoxin for the Treatment of Neuropathic Pain
por: Egeo, Gabriella, et al.
Publicado: (2020)

Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
por: Altamura, Claudia, et al.
Publicado: (2023)

O036. Cocaine and headache: a 2-year follow-up study in chronic cocaine users and literature review
por: Fofi, Luisa, et al.
Publicado: (2015)

A Randomized Clinical Trial on Acupuncture Versus Best Medical Therapy in Episodic Migraine Prophylaxis: The ACUMIGRAN Study
por: Giannini, Giulia, et al.
Publicado: (2021)

Calcitonin Gene-Related Peptide Systemic Effects: Embracing the Complexity of Its Biological Roles—A Narrative Review
por: Bonura, Adriano, et al.
Publicado: (2023)

P044. Anger expression in chronic daily headache patients with and without psychiatric comorbidity
por: Giannini, Giulia, et al.
Publicado: (2015)

PAND2 Test results
por: Bocci, V, et al.
Publicado: (1996)

P063. Colloid cysts of the third ventricle: a case report
por: de Pasqua, Silvia, et al.
Publicado: (2015)

EHMTI-0241. Association between migraine and sod1 and sod2 genes polymorphisms: the biobim study
por: Barbanti, P, et al.
Publicado: (2014)

Commentary: Enhanced Hemodynamic and Clinical Response to αCGRP in Migraine Patients—A TCD Study
por: Altamura, Claudia, et al.
Publicado: (2021)

O039. Case-control genetic association studies in migraine: a 7-year experience at the Interinstitutional Multidisciplinary Biobank (BioBIM) of IRCCS San Raffaele Pisana
por: Barbanti, Piero, et al.
Publicado: (2015)

Quantitative and Qualitative Pain Evaluation in Response to OnabotulinumtoxinA for Chronic Migraine: An Observational Real-Life Study
por: Altamura, Claudia, et al.
Publicado: (2023)

P037. Headache in multiple sclerosis: prevalence and clinical features in a case control-study
por: Terlizzi, Rossana, et al.
Publicado: (2015)

Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic
por: Baraldi, Carlo, et al.
Publicado: (2021)

The unforgivable curse of Harry Potter’s thunderclap headaches
por: Pensato, Umberto, et al.
Publicado: (2021)

Great occipital nerve long-acting steroid injections in cluster headache therapy: an observational prospective study
por: Merli, Elena, et al.
Publicado: (2021)

Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
por: Barbanti, Piero, et al.
Publicado: (2022)

Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
por: Barbanti, Piero, et al.
Publicado: (2022)

Look beyond Catechol-O-Methyltransferase genotype for cathecolamines derangement in migraine: the BioBIM rs4818 and rs4680 polymorphisms study
por: De Marchis, Maria Laura, et al.
Publicado: (2015)

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
por: Barbanti, Piero, et al.
Publicado: (2022)

Idiopathic Intracranial Hypertension Without Papilledema (IIHWOP) in Chronic Refractory Headache
por: Favoni, Valentina, et al.
Publicado: (2018)

Treatment of withdrawal headache in patients with medication overuse headache: a pilot study
por: Cevoli, Sabina, et al.
Publicado: (2017)

A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years
por: Piccinni, Carlo, et al.
Publicado: (2019)

Transverse Sinus Stenosis in Refractory Chronic Headache Patients: An Observational Study
por: Favoni, Valentina, et al.
Publicado: (2019)

The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD
por: Sun, Qingan, et al.
Publicado: (2020)

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
por: Favoni, Valentina, et al.
Publicado: (2019)

P027. Idiopathic intracranial hypertension without papilledema in refractory chronic daily headache
por: Favoni, Valentina, et al.
Publicado: (2015)

Combinatorial control of gene expression by the three yeast repressors Mig1, Mig2 and Mig3
por: Westholm, Jakub Orzechowski, et al.
Publicado: (2008)

Specification of the new DELPHI LTS-CB (PAND2 - F6907
por: Bocci, V, et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_98lvq3dbtg50rkcgl7im0h3gg9